Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity (2023 - 2025)

CG Oncology's Common Equity history spans 3 years, with the latest figure at $752.6 million for Q4 2025.

  • For Q4 2025, Common Equity rose 2.62% year-over-year to $752.6 million; the TTM value through Dec 2025 reached $752.6 million, up 2.62%, while the annual FY2025 figure was $752.6 million, 2.62% up from the prior year.
  • Common Equity reached $752.6 million in Q4 2025 per CGON's latest filing, up from $687.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $752.6 million in Q4 2025 to a low of -$123.1 million in Q4 2023.
  • Average Common Equity over 3 years is $399.4 million, with a median of $560.6 million recorded in 2024.
  • Peak YoY movement for Common Equity: surged 760.66% in 2024, then increased 2.62% in 2025.
  • A 3-year view of Common Equity shows it stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then increased by 2.62% to $752.6 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Common Equity are $752.6 million (Q4 2025), $687.6 million (Q3 2025), and $670.4 million (Q2 2025).